Exploring pre-existing immunity in cancer immunotherapy trials

A look at the role of pre-existing immunity in cancer immunotherapy trial readouts at ASCO17

August 8, 2017

Jumpstarting the immune system with synthetic immunity

Jumpstarting the immune system with a synthetic immunity approach - how can we do this?

August 2, 2017

A hidden gem at ASCO17

How can we boost the efficacy of checkpoint therapies? One way is to drive more activated T cells into the tumour.

August 1, 2017

A look at Nektar Therapeutics immunotherapy pipeline

Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline

July 24, 2017

Can epigenetic therapy boost cancer immunotherapy?

A look at the intersection of epigenetics and cancer immunotherapy - what can we learn and where are we going in this niche?

July 19, 2017

When targeted and immunotherapy worlds collide

A look at an up and coming small cap biotech developing targeted and immunotherapy agents for the treatment of cancer.

July 6, 2017

Gems from the ASCO17 Poster Hall Part 1

A look at how liver mets can negatively impact cancer immunotherapies

June 22, 2017

Can a vaccine make a difference in sarcoma?

What can we learn from the Immune Design data in sarcomas with their NY-ESO-1 vaccine?

June 21, 2017

New developments in sarcoma

What's new in the sarcoma space? Which novel approaches are worth watching out for?

June 20, 2017

A promising IO combo approach to watch out for

Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...

June 19, 2017

APHINITY – How much better and for whom?

Thought leader reactions and sentiments to the APHINITY readout in adjuvant HER2+ breast cancer

June 16, 2017

New IO developments in breast cancer

A look at checkpoint blockade in early stage breast cancer - encouraging or not?

June 14, 2017

Going beyond PARP monotherapies

A look at PARP as it journeys from 1999 to 2017 culminating in a plenary presentation at ASCO

June 13, 2017

An in-depth look at OLYMPIAD in HER2 negative breast cancer

Olaparib is the first PARP to demonstrate a clinical benefit in HER2- breast cancer - what do KOLs really think?

June 12, 2017

Trends, Highlights and Lowlights from ASCO 2017

Beyond the incremental improvements seen in clinical trials, what are the new trends emerging from ASCO 2017 that will impact oncology R&D?

June 6, 2017

ASCO17 Preview A Strategic Look at Emerging Themes

Right now many people are overwhelmed not just with the sheer number of ASCO abstracts to process and…

May 31, 2017

ASCO17 Top 10 Abstracts

Our Top 10 #ASCO17 abstracts to watch out for

May 26, 2017
Chicago River

ASCO 2017 CAR T Cell Therapy Preview

Some intriguing surprises in the CAR T cell therapy abstracts this year...

May 24, 2017
ASCO 2014 Chicago Contemplation

An up and coming area in early oncology R&D

A look at an up and coming niche in cancer research that may turn out to be useful in conjunction with checkpoint blockade

May 22, 2017

5 key abstracts to consider from ASCO 2017

A look at 5 key abstracts that tickled my fancy from #ASCO17; Warning - not all are positive!

May 18, 2017

ASCO 2017 Preview 2 – IDO1 Inhibitors

Update on #ASCO17 data for IDO1 inhibitors in various cancers

May 17, 2017

Things we need to think about ahead of ASCO17

A fireside chat with a leading KOL involved in cancer research on resistance.

May 16, 2017

Going Beyond PARP in DNA Damage Repair

A look a one company's approach to DDR and potential combination opportunities in this niche

May 9, 2017